Drug Profile
M 5
Alternative Names: Lys300His mutant pro-urokinase; M5Latest Information Update: 15 Nov 2012
Price :
$50
*
At a glance
- Originator Harvard Medical School
- Developer Harvard Medical School; Tomen
- Class Plasminogen activator enzymes
- Mechanism of Action Plasminogen activators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Thrombosis
Most Recent Events
- 15 Nov 2012 Discontinued - Preclinical for Thrombosis in Japan (unspecified route)
- 15 Nov 2012 Discontinued - Preclinical for Thrombosis in USA (unspecified route)
- 18 Apr 2000 Tomen has licensed M5 from Harvard Medical School for the world